Abstract
The 12th ICACT meeting was excellent in reviewing state-of-the-art management approaches to patients with cancer, and was also outstanding in presenting the rationale and background for many worldwide studies incorporating novel therapeutic approaches. The meeting also set the platform for understanding the mechanisms behind new therapeutic targets being used alone, or most likely in combination with existing therapies, and discussed the implications of their use in ongoing phase I, II, and trials.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 222-223 |
| Number of pages | 2 |
| Journal | IDrugs |
| Volume | 5 |
| Issue number | 3 |
| State | Published - 2002 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
Cite this
Anti-Cancer Treatment - 12th International Congress : 4-7 February 2002, Paris, France. / Perez, Edith A.
In: IDrugs, Vol. 5, No. 3, 2002, p. 222-223.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Anti-Cancer Treatment - 12th International Congress
T2 - 4-7 February 2002, Paris, France
AU - Perez, Edith A.
PY - 2002
Y1 - 2002
N2 - The 12th ICACT meeting was excellent in reviewing state-of-the-art management approaches to patients with cancer, and was also outstanding in presenting the rationale and background for many worldwide studies incorporating novel therapeutic approaches. The meeting also set the platform for understanding the mechanisms behind new therapeutic targets being used alone, or most likely in combination with existing therapies, and discussed the implications of their use in ongoing phase I, II, and trials.
AB - The 12th ICACT meeting was excellent in reviewing state-of-the-art management approaches to patients with cancer, and was also outstanding in presenting the rationale and background for many worldwide studies incorporating novel therapeutic approaches. The meeting also set the platform for understanding the mechanisms behind new therapeutic targets being used alone, or most likely in combination with existing therapies, and discussed the implications of their use in ongoing phase I, II, and trials.
UR - http://www.scopus.com/inward/record.url?scp=0141784084&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141784084&partnerID=8YFLogxK
M3 - Article
C2 - 15562331
AN - SCOPUS:0141784084
VL - 5
SP - 222
EP - 223
JO - IDrugs : the investigational drugs journal
JF - IDrugs : the investigational drugs journal
SN - 1369-7056
IS - 3
ER -